Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Data-Driven Harmonization of 2022 Who and ICC Classifications of Myelodysplastic Syndromes/Neoplasms (MDS): A Study By the International Consortium for MDS (icMDS)

Luca Lanino, Somedeb Ball, Jan Philipp Bewersdorf, Monia Marchetti, Giulia Maggioni, Erica Travaglino, Najla H Al Ali, Pierre Fenaux, Uwe Platzbecker, Valeria Santini, Maria Diez-Campelo, Avani M Singh, Akriti Gupta Jain, Luis E. Aguirre, Sara M. Tinsley-Vance, Zaker I. Schwabkey, Onyee Chan, Zhuoer Xie, Andrew M. Brunner, Andrew T. Kuykendall, John M. Bennett, Rena Buckstein, Rafael Bejar, Hetty E. Carraway, Amy E. DeZern, Elizabeth A. Griffiths, Stephanie Halene, Robert Hasserjian, Jeffrey Lancet, Alan F. List, Sanam Loghavi, Olatoyosi Odenike, Eric Padron, Mrinal M. Patnaik, Gail J. Roboz, Maximilian Stahl, Mikkael A. Sekeres, David Peter Steensma, Michael R. Savona, Justin Taylor, Mina Xu, Kendra Sweet, David A Sallman, Stephen D. Nimer, Christopher S. Hourigan, Andrew H. Wei, Elisabetta Sauta, Saverio D'Amico, Gianluca Asti, Gastone Castellani, Uma M. Borate, Guillermo Sanz, Fabio Efficace, Steven D. Gore, Tae Kon Kim, Naval Daver, Guillermo Garcia-Manero, María Rozman, Alberto Orfao, Sa A. Wang, M. Kathy Foucar, Ulrich Germing, Torsten Haferlach, Phillip Scheinberg, Yasushi Miyazaki, Marcelo Iastrebner, Austin Kulasekararaj, Thomas Cluzeau, Shahram Kordasti, Arjan A. van de Loosdrecht, Lionel Ades, Amer M. Zeidan, Rami S. Komrokji, Matteo Giovanni Della Porta

Blood (2023) 142 (Supplement 1): 998.

https://doi.org/10.1182/blood-2023-186580

Published: 2023

Journal Articles

Improved Overall Survival Among Luspatercept Responders and Predictors of Response

Blood (2023) 142 (Supplement 1): 1871.

https://doi.org/10.1182/blood-2023-186279

Published: 2023

Journal Articles

Outcomes in Patients with Acute Myeloid Leukemia Treated with CLAG (cladribine, cytarabine, filgrastim) and/or Mitoxantrone with Venetoclax

Onyee Chan, Luis E. Aguirre, Mary Burke, Najla H Al Ali, Zhuoer Xie, Seongseok Yun, Andrew T. Kuykendall, Eric Padron, Alison R. Walker, Jeffrey Lancet, Rami S. Komrokji, David A Sallman

Blood (2023) 142 (Supplement 1): 5935.

https://doi.org/10.1182/blood-2023-173637

Published: 2023

Journal Articles

Characterization of TP53 -Mutated Myelodysplastic Syndromes and Impact of Allelic Status and Concurrent Cytogenetic Abnormalities on Survival Outcomes

Luis E. Aguirre, Najla Al Ali, Akriti G Jain, Onyee Chan, Somedeb Ball, Andrew Kuykendall, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, Rami S. Komrokji, David A. Sallman

Blood (2022) 140 (Supplement 1): 4034–4035.

https://doi.org/10.1182/blood-2022-171093

Published: 2022

Journal Articles

Synergistic Activity of Luspatercept and Erythroid Stimulating Agents Combination for Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes

Rami S. Komrokji, Luis E. Aguirre, Najla Al Ali, Onyee Chan, Andrew Kuykendall, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, David A. Sallman

Blood (2022) 140 (Supplement 1): 6917–6919.

https://doi.org/10.1182/blood-2022-169560

Published: 2022

Journal Articles

Assessment of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model in Hypoplastic Myelodysplastic Syndromes

Luis E. Aguirre, Najla Al Ali, Somedeb Ball, Avani M Singh, Akriti G Jain, Onyee Chan, Zaker I. Schwabkey, Sara M Tinsley-Vance, Andrew Kuykendall, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, David A. Sallman, Rami S. Komrokji

Blood (2022) 140 (Supplement 1): 6909–6911.

https://doi.org/10.1182/blood-2022-171044

Published: 2022

Journal Articles

Drivers of Deep Molecular Response and Outcomes in Patients with Core Binding Factor Acute Myeloid Leukemia

Somedeb Ball, Akriti G Jain, Parth C. Patel, Chen Wang, Luis E. Aguirre, Mohammad O Hussaini, Onyee Chan, Seongseok Yun, Andrew Kuykendall, Eric Padron, Kendra Sweet, Jeffrey E. Lancet, Rami S. Komrokji, David A. Sallman

Blood (2022) 140 (Supplement 1): 6282–6284.

https://doi.org/10.1182/blood-2022-170442

Published: 2022

Journal Articles

Subclonal KIT D816V Mutations Are Prevalent in Chronic Myelomonocytic Leukemia and Correlate with Distinct Phenotypic Features

Blood (2022) 140 (Supplement 1): 9824–9827.

https://doi.org/10.1182/blood-2022-164816

Published: 2022

Journal Articles

Assessment of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model in Therapy-Related Myelodysplastic Syndromes

Blood (2022) 140 (Supplement 1): 9813–9815.

https://doi.org/10.1182/blood-2022-170980

Published: 2022

Journal Articles

Validation of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model for Myelodysplastic Syndromes

Blood (2022) 140 (Supplement 1): 1125–1127.

https://doi.org/10.1182/blood-2022-170878

Published: 2022

Journal Articles

A Product of "Clash of Titans" or True Reflection of Disease Biology? Validation of 2022 WHO and ICC Classifications in a Large Dataset of Patients with Myelodysplastic Syndrome

Somedeb Ball, Avani M Singh, Najla Al Ali, Luis E. Aguirre, Akriti G Jain, Zaker I. Schwabkey, Sara M Tinsley-Vance, Onyee Chan, Andrew Kuykendall, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, David A. Sallman, Rami S. Komrokji

Blood (2022) 140 (Supplement 1): 1118–1120.

https://doi.org/10.1182/blood-2022-170158

Published: 2022

Journal Articles

Hypoplastic MDS: Validation of the New World Health Organization 2022 Proposal

Zaker I. Schwabkey, Amin Azem, Najla Al Ali, Somedeb Ball, Luis E. Aguirre, Akriti G Jain, Avani M Singh, Sara M Tinsley-Vance, Onyee Chan, Jeffrey E. Lancet, Kendra Sweet, Andrew Kuykendall, Eric Padron, David A. Sallman, Rami S. Komrokji

Blood (2022) 140 (Supplement 1): 6974–6975.

https://doi.org/10.1182/blood-2022-156974

Published: 2022

Journal Articles

Clinico-Molecular Features and Treatment Outcomes in Primary Myelofibrosis Phenotypes with Protracted Disease Dynamics

Luis E. Aguirre, Akriti G Jain, Somedeb Ball, Najla Al Ali, Sara Marie Tinsley-Vance, David A. Sallman, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, Andrew T. Kuykendall, Rami S. Komrokji

Blood (2021) 138 (Supplement 1): 2571.

https://doi.org/10.1182/blood-2021-152026

Published: 2021

Journal Articles

The Natural History of Lower Risk MDS: Factors Predicting Progression to High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia in Patients with Very Low and Low Risk MDS According to the R-IPSS Criteria

Akriti G Jain, Somedeb Ball, Luis E. Aguirre, Najla Al Ali, David Kaldas, Sara Tinsley-Vance, Andrew T. Kuykendall, Onyee Chan, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, David A. Sallman, Rami S. Komrokji

Blood (2021) 138 (Supplement 1): 2600.

https://doi.org/10.1182/blood-2021-149708

Published: 2021

Journal Articles

Characterization of Indolent Chronic Myelomonocytic Leukemia Phenotypes and Identification of Dynamic Disease Features of Progression and Need for Treatment

Luis E. Aguirre, Somedeb Ball, Akriti G Jain, Najla Al Ali, David A. Sallman, Andrew T. Kuykendall, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, Rami S. Komrokji

Blood (2021) 138 (Supplement 1): 1523.

https://doi.org/10.1182/blood-2021-149283

Published: 2021

Journal Articles

Hypogammaglobulinemia and Its Implications in Patients Treated with Daratumumab: A Single Institution Experience

Yonette Paul, MD MBBS, Luis E. Aguirre, MD, Fahmin Basher, MD PhD, Feng Miao, MS, Tulay Koru-Sengul, PhD, James E. Hoffman, MD

Blood (2019) 134 (Supplement_1): 3131.

https://doi.org/10.1182/blood-2019-127247

Published: 2019

NARROW

Data-Driven Harmonization of 2022 Who and ICC Classifications of Myelodysplastic Syndromes/Neoplasms (MDS): A Study By the International Consortium for MDS (icMDS)

Improved Overall Survival Among Luspatercept Responders and Predictors of Response

Outcomes in Patients with Acute Myeloid Leukemia Treated with CLAG (cladribine, cytarabine, filgrastim) and/or Mitoxantrone with Venetoclax

Characterization of TP53 -Mutated Myelodysplastic Syndromes and Impact of Allelic Status and Concurrent Cytogenetic Abnormalities on Survival Outcomes

Synergistic Activity of Luspatercept and Erythroid Stimulating Agents Combination for Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes

Assessment of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model in Hypoplastic Myelodysplastic Syndromes

Drivers of Deep Molecular Response and Outcomes in Patients with Core Binding Factor Acute Myeloid Leukemia

Subclonal KIT D816V Mutations Are Prevalent in Chronic Myelomonocytic Leukemia and Correlate with Distinct Phenotypic Features

Assessment of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model in Therapy-Related Myelodysplastic Syndromes

Validation of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model for Myelodysplastic Syndromes

A Product of "Clash of Titans" or True Reflection of Disease Biology? Validation of 2022 WHO and ICC Classifications in a Large Dataset of Patients with Myelodysplastic Syndrome

Hypoplastic MDS: Validation of the New World Health Organization 2022 Proposal

Clinico-Molecular Features and Treatment Outcomes in Primary Myelofibrosis Phenotypes with Protracted Disease Dynamics

The Natural History of Lower Risk MDS: Factors Predicting Progression to High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia in Patients with Very Low and Low Risk MDS According to the R-IPSS Criteria

Characterization of Indolent Chronic Myelomonocytic Leukemia Phenotypes and Identification of Dynamic Disease Features of Progression and Need for Treatment

Hypogammaglobulinemia and Its Implications in Patients Treated with Daratumumab: A Single Institution Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only